These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 29851442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of formulary restrictions on medication use and costs.
    Shen X, Stuart BC, Powers CA, Tom SE, Magder LS, Perfetto EM.
    Am J Manag Care; 2017 Aug 01; 23(8):e265-e274. PubMed ID: 29087150
    [Abstract] [Full Text] [Related]

  • 3. Does the offer of free prescriptions increase generic prescribing?
    Stuart B, Hendrick F, Dougherty JS, Xu J.
    Am J Manag Care; 2017 Jun 01; 23(6):e193-e201. PubMed ID: 28817295
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans?
    Chou J, Brandt NJ, Loh FE, Stuart B.
    Consult Pharm; 2017 Feb 01; 32(2):109-118. PubMed ID: 28569663
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
    Luo J, Feldman R, Rothenberger SD, Hernandez I, Gellad WF.
    JAMA Netw Open; 2020 Oct 01; 3(10):e2020969. PubMed ID: 33057641
    [Abstract] [Full Text] [Related]

  • 16. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A, Navarro-Artieda R.
    Rev Peru Med Exp Salud Publica; 2014 Oct 01; 31(4):626-34. PubMed ID: 25597711
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT.
    Ann Intern Med; 2015 Nov 03; 163(9):663-72. PubMed ID: 26457538
    [Abstract] [Full Text] [Related]

  • 19. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.
    Curr Med Res Opin; 2010 Jul 03; 26(7):1697-703. PubMed ID: 20465367
    [Abstract] [Full Text] [Related]

  • 20. Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
    Feldman WB, Rome BN, Lehmann LS, Kesselheim AS.
    JAMA Intern Med; 2020 Apr 01; 180(4):597-601. PubMed ID: 32011624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.